Imatinib treats chronic myeloid leukemia (CML) by inhibiting the BCR-ABL1 fusion protein that is a deregulated tyrosine kinase resulting from the Philadelphia chromosome (Quintás-Cardama and Cortes 2009). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.